Applied Genetic Technologies Corporation
| NASDAQ: AGTC | Healthcare / Biotechnology / USA |
| 3.80 | -0.1900 | -4.76% | Vol 1.93M | 1Y Perf -6.63% |
| Apr 19th, 2021 16:00 DELAYED |
| BID | 3.73 | ASK | 3.85 | ||
| Open | 3.92 | Previous Close | 3.99 | ||
| Pre-Market | - | After-Market | 3.77 | ||
| - - | -0.03 -0.79% |
| Target Price | 17.33 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 356.05 | Finscreener Ranking | ★★ 46.71 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★ 41.30 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★+ 38.89 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 162.46M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 3.93 | Earnings Date | 12th May 2021 |
Today's Price Range 3.673.94 | 52W Range 3.569.67 | 5 Year PE Ratio Range -47.00575.00 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -5.24% | ||
| 1 Month | -37.09% | ||
| 3 Months | -18.45% | ||
| 6 Months | -28.57% | ||
| 1 Year | -6.63% | ||
| 3 Years | -24.00% | ||
| 5 Years | -76.84% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -14.58 | |||
ROE last 12 Months | -105.78 | |||
ROA (5Y Avg) | -18.67 | |||
ROA last 12 Months | -70.00 | |||
ROC (5Y Avg) | -15.71 | |||
ROC last 12 Months | -92.75 | |||
Return on invested Capital Q | -23.92 | |||
Return on invested Capital Y | -55.38 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | -7.30 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.80 | ||||
| 4.11 | ||||
| 46.12 | ||||
| 1.80 | ||||
| -4.20 | ||||
| -1.96 | ||||
| 4.11 | ||||
| 0.97 | ||||
| 132.18M | ||||
| Forward PE | -2.40 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.70 | ||||
| 3.90 | ||||
| 0.25 | ||||
| 0.35 | ||||
| -83.60 | ||||
| Leverage Ratio | 1.80 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| -2 054.50 | ||||
| -1 997.60 | ||||
| -390.70 | ||||
| -80.91 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| -55.10 | ||||
| -29.63 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2021 | -0.59 | -0.60 | -1.69 |
| Q01 2021 | -0.51 | -0.60 | -17.65 |
| Q04 2020 | -0.46 | -0.56 | -21.74 |
| Q03 2020 | -0.55 | -0.50 | 9.09 |
| Q02 2020 | -0.59 | -0.47 | 20.34 |
| Q01 2020 | -0.58 | -0.64 | -10.34 |
| Q04 2019 | -0.51 | -0.58 | -13.73 |
| Q03 2019 | -0.54 | 0.63 | 216.67 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -0.41 | 18.00 | Positive |
| 6/2021 QR | -0.41 | 14.58 | Positive |
| 6/2021 FY | -1.93 | 8.53 | Positive |
| 6/2022 FY | -1.66 | 23.15 | Positive |
| Next Report Date | 12th May 2021 |
| Estimated EPS Next Report | -0.41 |
| Estimates Count | 4 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.93M |
| Shares Outstanding | 42.75M |
| Trades Count | 12.07K |
| Dollar Volume | 16.47M |
| Avg. Volume | 2.92M |
| Avg. Weekly Volume | 1.93M |
| Avg. Monthly Volume | 1.41M |
| Avg. Quarterly Volume | 3.40M |
Applied Genetic Technologies Corporation (NASDAQ: AGTC) stock closed at 3.8 per share at the end of the most recent trading day (a -4.76% change compared to the prior day closing price) with a volume of 1.94M shares and market capitalization of 162.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 83 people. Applied Genetic Technologies Corporation CEO is Susan B. Washer.
The one-year performance of Applied Genetic Technologies Corporation stock is -6.63%, while year-to-date (YTD) performance is -7.09%. AGTC stock has a five-year performance of -76.84%. Its 52-week range is between 3.56 and 9.67, which gives AGTC stock a 52-week price range ratio of 3.93%
Applied Genetic Technologies Corporation currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 4.11, a price-to-sale (PS) ratio of 46.12, a price to cashflow ratio of 1.80, a PEG ratio of 2.32, a ROA of -70.00%, a ROC of -92.75% and a ROE of -105.78%. The company’s profit margin is -80.91%, its EBITDA margin is -1 997.60%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Applied Genetic Technologies Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Applied Genetic Technologies Corporation’s next earnings report date is 12th May 2021.
The consensus rating of Wall Street analysts for Applied Genetic Technologies Corporation is Strong Buy (1), with a target price of $17.33, which is +356.05% compared to the current price. The earnings rating for Applied Genetic Technologies Corporation stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Applied Genetic Technologies Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Applied Genetic Technologies Corporation has a Sell technical analysis rating based on Technical Indicators (ADX : 14.68, ATR14 : 0.61, CCI20 : -125.19, Chaikin Money Flow : -0.10, MACD : -0.39, Money Flow Index : 18.67, ROC : -25.05, RSI : 41.83, STOCH (14,3) : 8.14, STOCH RSI : 0.00, UO : 43.15, Williams %R : -91.86), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Applied Genetic Technologies Corporation in the last 12-months were:
Applied Genetic Technologies Corporation
Applied Genetic Technologies Corp is a clinical-stage biotechnology company that uses a proprietary gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. Its initial focus is in the field of ophthalmology, where it has active clinical trials in X-linked retinitis pigmentosa, achromatopsia (ACHM CNGB3 and ACHM CNGA3), and X-linked retinoschisis. In addition to its clinical trials, company has preclinical programs in optogenetics, adrenoleukodystrophy, which is a disease of the central nervous system, other ophthalmology, and otology indications. The optogenetics program is being developed in collaboration with Bionic Sight.
CEO: Susan B. Washer
Telephone: +1 386 462-2204
Address: 14193 NW 119th Terrace, Alachua 32615, FL, US
Number of employees: 83
